The emerging pipeline for the treatment of Adenoid Cystic Carcinoma is robust. Pharmaceutical companies like Merck, Ayala Pharmaceuticals, etc., are investigating many combination products in this disease area.
DelveInsight’s “Adenoid Cystic Carcinoma (ACC) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Adenoid Cystic Carcinoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Adenoid Cystic Carcinoma market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Adenoid Cystic Carcinoma: An Overview
Adenoid cystic carcinoma (ACC) is a rare form of adenocarcinoma that begins in the glandular tissue. It commonly develops in the salivary glands or other regions of the head and neck but can also occur in other parts of the body. ACC tumors are characterized by a distinctive histological pattern of abnormal “nests” or cords of epithelial cells that surround or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes, apparent during the microscopic evaluation of tumor cells.
ACC is a low-grade malignancy with slow growth. It is rarely invasive and infiltrates nearby lymph nodes and perineural spaces, but it has a tendency for local recurrence, and in approximately half of the patients, it spreads to distant bodily sites, particularly the lungs, resulting in life-threatening complications. Unlike most carcinomas, most patients with ACC survive for 5 years, only to have tumors recur and progress.
Adenoid Cystic Carcinoma Market Key Facts
According to Calderón Boyle et al. (2020), in the US, the Adenoid Cystic Carcinoma incidence rate was 0.35 per 100,000. Adenoid Cystic Carcinoma limited duration prevalence was highest in those aged 75–79 years and in females and lowest among Native Americans/Alaska Natives. Adenoid Cystic Carcinoma cases were highest in the oral cavity and pharynx.
According to Inagaki et al. (2020) study of Adenoid Cystic Carcinoma cases of salivary gland origin in Japan, 5-year overall survival (OS) and disease-free survival (DFS) rates were 92.5% and 50.0%, respectively, with treatment failure in 46% cases while distant failures in 34%.
Several major pharma and biotech companies are working in the Adenoid Cystic Carcinoma Market, such as Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, Merck & Co, and others.
Adenoid Cystic Carcinoma Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Adenoid Cystic Carcinoma market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Adenoid Cystic Carcinoma market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Adenoid Cystic Carcinoma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Adenoid Cystic Carcinoma Epidemiology, Segmented as –
Total Incidence Cases of ACC in the 7MM [2019–2032]
Gender-specific Incidence cases of ACC in the 7MM [2019–2032]
Grade-specific Incidence cases of ACC in the 7MM [2019-2032]
Treatable cases of ACC in the 7MM [2019-2032]
Adenoid Cystic Carcinoma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Adenoid Cystic Carcinoma market or expected to be launched during the study period. The analysis covers the Adenoid Cystic Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Adenoid Cystic Carcinoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Adenoid Cystic Carcinoma Market Will Evolve and Grow by 2032 @
Adenoid Cystic Carcinoma Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Adenoid Cystic Carcinoma. Ayala Pharmaceuticals is leading the therapeutics market with its Adenoid Cystic Carcinoma drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Adenoid Cystic Carcinoma Therapeutics Market Include:
Merck & Co.
And Many Others
Adenoid Cystic Carcinoma Emerging and Marketed Drugs Covered in the Report Include:
Rivoceranib : HLB
Lenvatinib and Pembrolizumab: Merck
AL101: Ayala Pharmaceuticals
AMG 232 : Amgen
CV8102: CureVac AG
Elraglusib: Actuate Therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Adenoid Cystic Carcinoma Competitive Intelligence Analysis
4. Adenoid Cystic Carcinoma Market Overview at a Glance
5. Adenoid Cystic Carcinoma Disease Background and Overview
6. Adenoid Cystic Carcinoma Patient Journey
7. Adenoid Cystic Carcinoma Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Adenoid Cystic Carcinoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Adenoid Cystic Carcinoma Unmet Needs
10. Key Endpoints of Adenoid Cystic Carcinoma Treatment
11. Adenoid Cystic Carcinoma Marketed Products
12. Adenoid Cystic Carcinoma Emerging Drugs and Latest Therapeutic Advances
13. Adenoid Cystic Carcinoma Seven Major Market Analysis
14. Attribute Analysis
15. Adenoid Cystic Carcinoma Market Outlook (In US, EU5, and Japan)
16. Adenoid Cystic Carcinoma Access and Reimbursement Overview
17. KOL Views on the Adenoid Cystic Carcinoma Market
18. Adenoid Cystic Carcinoma Market Drivers
19. Adenoid Cystic Carcinoma Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Strategies
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States